Athira Pharma Inc Asset Resilience Ratio
Athira Pharma Inc asset resilience ratio. Athira Pharma Inc (ATHA) has an Asset Resilience Ratio of 20.68% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Athira Pharma Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Athira Pharma Inc (2018–2025)
Asset resilience ratio of Athira Pharma Inc from 2018 to 2025. This chart shows how Athira Pharma Inc's Asset Resilience Ratio has changed over time. Read ATHA current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Athira Pharma Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ATHA asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $19.05 Million | 20.68% |
| Total Liquid Assets | $19.05 Million | 20.68% |
Asset Resilience Insights
- Good Liquidity Position: Athira Pharma Inc maintains a healthy 20.68% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Athira Pharma Inc Industry Peers by Asset Resilience Ratio
Compare Athira Pharma Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Athira Pharma Inc Asset Resilience Ratio by Year (2018–2025)
Athira Pharma Inc asset resilience ratio by year from 2018 to 2025. The table below shows the annual Asset Resilience Ratio data for Athira Pharma Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 20.68% | $19.05 Million | $92.15 Million | +15.85pp |
| 2024-12-31 | 4.83% | $2.84 Million | $58.78 Million | -30.64pp |
| 2023-12-31 | 35.47% | $56.84 Million | $160.25 Million | -4.97pp |
| 2022-12-31 | 40.43% | $104.38 Million | $258.15 Million | -2.71pp |
| 2021-12-31 | 43.14% | $143.22 Million | $332.01 Million | -1.24pp |
| 2020-12-31 | 44.38% | $124.06 Million | $279.56 Million | -- |
| 2019-12-31 | 0.00% | $0.00 | $2.19 Million | -- |
| 2018-12-31 | 30.41% | $1.50 Million | $4.93 Million | -- |
About Athira Pharma Inc
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds… Read more